Aquestive Therapeutics, Inc. (AQST): Price and Financial Metrics


Aquestive Therapeutics, Inc. (AQST): $4.17

0.02 (+0.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AQST POWR Grades


  • Sentiment is the dimension where AQST ranks best; there it ranks ahead of 82.85% of US stocks.
  • AQST's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • AQST ranks lowest in Stability; there it ranks in the 9th percentile.

AQST Stock Summary

  • Aquestive Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 4.01% of US listed stocks.
  • Aquestive Therapeutics Inc's stock had its IPO on July 25, 2018, making it an older stock than just 8.85% of US equities in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.27 for Aquestive Therapeutics Inc; that's greater than it is for just 4.52% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aquestive Therapeutics Inc are QMCO, AGE, ITGR, PAR, and AVGR.
  • AQST's SEC filings can be seen here. And to visit Aquestive Therapeutics Inc's official web site, go to www.aquestive.com.

AQST Valuation Summary

  • AQST's price/sales ratio is 4.3; this is 13.16% higher than that of the median Healthcare stock.
  • Over the past 38 months, AQST's price/earnings ratio has gone up 30.9.
  • AQST's EV/EBIT ratio has moved up 328.9 over the prior 38 months.

Below are key valuation metrics over time for AQST.

Stock Date P/S P/B P/E EV/EBIT
AQST 2021-08-31 4.3 -3.3 -2.8 -5.5
AQST 2021-08-30 4.3 -3.4 -2.8 -5.5
AQST 2021-08-27 3.8 -2.9 -2.5 -5.0
AQST 2021-08-26 3.7 -2.9 -2.4 -4.9
AQST 2021-08-25 3.7 -2.9 -2.4 -4.9
AQST 2021-08-24 3.6 -2.8 -2.4 -4.9

AQST's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AQST has a Quality Grade of C, ranking ahead of 62.96% of graded US stocks.
  • AQST's asset turnover comes in at 0.692 -- ranking 38th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows AQST's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.692 0.690 -0.456
2021-03-31 0.808 0.750 -0.415
2020-12-31 0.760 0.717 -0.515
2020-09-30 0.858 0.692 -0.487
2020-06-30 0.929 0.686 -0.524
2020-03-31 0.805 0.579 -0.867

AQST Price Target

For more insight on analysts targets of AQST, see our AQST price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.20 Average Broker Recommendation 1.4 (Strong Buy)

AQST Stock Price Chart Interactive Chart >

Price chart for AQST

AQST Price/Volume Stats

Current price $4.17 52-week high $9.10
Prev. close $4.15 52-week low $3.10
Day low $4.09 Volume 334,200
Day high $4.29 Avg. volume 707,842
50-day MA $3.87 Dividend yield N/A
200-day MA $4.65 Market Cap 162.15M

Aquestive Therapeutics, Inc. (AQST) Company Bio


Aquestive Therapeutics, Inc. operates as a specialty pharmaceutical company that specializes in the drug delivery technology. The company offers PharmFilm, a drug delivery platform/pharmaceutical dosage form that delivers existing prescription products directly to the bloodstream. It develops, manufactures, and commercializes pharmaceutical films, individual film doses, and finished products for patients, physicians, and caregivers. Aquestive Therapeutics, Inc. was formerly known as MonoSol Rx Inc. and changed its name to Aquestive Therapeutics, Inc. in November 2017. The company was founded in 2000 and is based in Warren, New Jersey.


AQST Latest News Stream


Event/Time News Detail
Loading, please wait...

AQST Latest Social Stream


Loading social stream, please wait...

View Full AQST Social Stream

Latest AQST News From Around the Web

Below are the latest news stories about Aquestive Therapeutics Inc that investors may wish to consider to help them evaluate AQST as an investment opportunity.

Aquestive Therapeutics to Participate in Three Investor Conferences in September

WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in three upcoming investor conferences in September as follows: H.C. Wainwright 23rd Annual Global Investment Conference: on demand corporate presentation available from September 13 - 15Lak

Yahoo | September 7, 2021

What Kind Of Shareholders Hold The Majority In Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares?

Every investor in Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) should be aware of the most powerful shareholder groups...

Yahoo | September 3, 2021

12 Health Care Stocks Moving In Monday''s Intraday Session

Gainers Valneva (NASDAQ: VALN ) stock moved upwards by 29.61% to $49.9 during Monday''s regular session. Valneva''s stock is trading at a volume of 143.0K shares as of 12:34 EST. This is 1342.64% of its average full-day volume over the last 100 days. The company''s market cap stands at $2.4 billion. Dermata Therapeutics (NASDAQ: DRMA ) stock moved upwards by 15.12% to $6.09. The market value of their outstanding shares is at $50.7 million. Aquestive Therapeutics (NASDAQ: AQST ) stock increased by 14.1% to $4.61. Trading volume for Aquestive Therapeutics''s stock is 1.4 million as of 12:34 EST. This is 272.83% of its average full-day volume over the last 100 days. The company''s market cap stands at $179.2 million. Owlet (NYSE: OWLT ) shares moved upwards by 12.15% to $6.83. The market v...

Benzinga | August 30, 2021

Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant Related Capital Under Current Debt Agreement

WARREN, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that it has reached an agreement with its lenders to amend the base indenture providing an extension of the term by six months to June 30, 2022 to provide additional debt in the aggregate of up to $30.0 million. In line with the extension to June 30, 2022, Aquestive is entitled, at its option, to draw up to $10 million following FDA approval for Libervant, the first orally delivered diazepam product for the management of seizure clusters, and up to an additional $20 million following the FDA grant of U.S. market access for Li...

Intrado Digital Media | August 9, 2021

Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant™ Related Capital Under Current Debt Agreement

Provides access to $30 million in capital contingent on FDA approval and U.S. market access for Libervant WARREN, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it has reached an agreement with its lenders to amend the base indenture providing an extension of the term by six months

Yahoo | August 9, 2021

Read More 'AQST' Stories Here

AQST Price Returns

1-mo 14.25%
3-mo 0.48%
6-mo -4.36%
1-year -53.92%
3-year -74.46%
5-year N/A
YTD -22.06%
2020 -8.08%
2019 -7.62%
2018 N/A
2017 N/A
2016 N/A

Continue Researching AQST

Want to see what other sources are saying about Aquestive Therapeutics Inc's financials and stock price? Try the links below:

Aquestive Therapeutics Inc (AQST) Stock Price | Nasdaq
Aquestive Therapeutics Inc (AQST) Stock Quote, History and News - Yahoo Finance
Aquestive Therapeutics Inc (AQST) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7615 seconds.